A Phase 2 clinical trial testing PIPE-307, an MS experimental therapy designed to promote myelin repair, failed to meet its ...

Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. | Contineum Therapeutics’ M1 receptor ...

A clinical trial testing an experimental vaccine for the Epstein-Barr virus (EBV) in people with MS is now recruiting ...

While expressing disappointment, William Blair analysts were unsurprised by the Phase II failure, having assigned the VISTA study a high level of risk given the “mixed” performance of a similar drug ...

The UK is launching a groundbreaking Horizon trial to see if a vaccine can help people with multiple sclerosis by targeting ...

A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...

Please provide your email address to receive an email when new articles are posted on . Less than 1% of current MS-based literature is focused on underrepresented groups. The CHIMES trial specifically ...

Nearly one in five stable MS patients developed significant radiological inflammation after stopping first-line treatment. The median time to disease activity after discontinuing treatment was 12 ...

CHICAGO — Abbott Laboratories and its Massachusetts biotech partner have launched a final-stage clinical trial of their experimental treatment for multiple sclerosis. The first of an eventual 1,500 ...